Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2
Yu. Yu. Polyakov,
E. A. Baryakh,
E. N. Misyurina,
E. I. Zhelnova,
M. A. Mingalimov,
S. A. Kardovskaya,
M. Ya. Smolyarchuk,
T. N. Tolstykh,
T. S. Chudnova,
D. D. Ivanova,
O. L. Kochneva,
D. V. Lebedev,
A. U. Abueva,
A. M. Chistov,
E. N. Zotina,
I. V. Samsonova,
M. A. Lysenko https://doi.org/10.17650/1818-8346-2024-19-2-101-108
Abstract
Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.
About the Authors
Yu. Yu. Polyakov
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Yuriy Yu. Polyakov.
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. A. Baryakh
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991; Build. 1, 2/1 Barrikadnaya St., Moscow 125993
E. N. Misyurina
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. I. Zhelnova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
M. A. Mingalimov
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
S. A. Kardovskaya
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
M. Ya. Smolyarchuk
Medicine and Nuclear Technologies LLC
Russian Federation
Russian Federation
Build. 322, 1 Akademika Kurchatova Ploshchad’, Moscow 123098
T. N. Tolstykh
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
T. S. Chudnova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
D. D. Ivanova
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
O. L. Kochneva
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
D. V. Lebedev
City Clinical Hospital No. 52, Moscow Healthcare Department; Medical and Biological University of Innovation and Continuing Education, State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; 46 Zhivopisnaya St., Moscow 123098
A. U. Abueva
City Clinical Hospital No. 52, Moscow Healthcare Department; Peoples’ Friendship University of Russia named after Patrice Lumumba
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; 6 Miklukho-Maklaya St., Moscow 117198
A. M. Chistov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1 Ostrovityanova St., Moscow 117997
E. N. Zotina
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
I. V. Samsonova
City Clinical Hospital No. 52, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; 1 Ostrovityanova St., Moscow 117997
M. A. Lysenko
City Clinical Hospital No. 52, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; 1 Ostrovityanova St., Moscow 117997
References
1. García L.F. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol 2020;11:1441. DOI: 10.3389/fimmu.2020.01441
2. Forrester J.V., Xu H., Lambe T., Cornall R. Immune privilege or privileged immunity? Mucosal Immunol 2008;1(5):372–81. DOI: 10.1038/mi.2008.27
3. Li N., Wang X., Lv T. Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon. J Med Virol 2020;92(11):2286–7. DOI: 10.1002/jmv.25952
4. Salmon-Ceron D., Slama D., de Broucker T. et al. Clinical virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study. J Infect 2021;82(2):e1–4. DOI: 10.1016/j.jinf.2020.12.002
5. Helleberg M., Niemann C.U., Moestrup K.S. et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis 2020;222(7):1103–7. DOI: 10.1093/infdis/jiaa446
6. Sepulcri C., Dentone C., Mikulska M. et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient – a case study. Open Forum Infect Dis 2021;8(11):ofab217. DOI: 10.1093/ofid/ofab217
Review
For citations:
Polyakov Yu.Yu., Baryakh E.A., Misyurina E.N., Zhelnova E.I., Mingalimov M.A., Kardovskaya S.A., Smolyarchuk M.Ya., Tolstykh T.N., Chudnova T.S., Ivanova D.D., Kochneva O.L., Lebedev D.V., Abueva A.U., Chistov A.M., Zotina E.N., Samsonova I.V., Lysenko M.A. Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2. Oncohematology. 2024;19(2):101-108. (In Russ.) https://doi.org/10.17650/1818-8346-2024-19-2-101-108
Views:
1429
Email this article 